BOSTON (Thomson Financial) - Hana Biosciences Inc. Monday said the European Commission has granted orphan medical product designation to Marqibo for the treatment of adult acute lymphoblastic leukemia.
The South San Francisco, Calif.-based biopharmaceutical company is currently enrolling patients in its registration-enabling Phase 2 'rALLy' clinical trial of Marqibo in patients with relapsed acute lymphoblastic leukemia.
Hana Biosciences expects to report a futility analysis from the Phase 2 trial during the second half of 2008.
Shares closed Friday at 66 cents. Casey Logan cl/tk1 COPYRIGHT Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.